Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience - Archive ouverte HAL Access content directly
Journal Articles United European Gastroenterology Journal Year : 2019

Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience

, (1) , (2) , (3) , (3) , , , (4) , (3) , (1)
1
2
3
4

Abstract

BACKGROUND: No study has evaluated the direct annual costs of inflammatory bowel disease patients treated with anti-tumour necrosis factor therapy. OBJECTIVES: The purpose of this study was to identify annual direct costs and main cost drivers of anti-tumour necrosis factor-treated inflammatory bowel disease patients. METHODS: All inflammatory bowel disease patients treated with infliximab or adalimumab at Nancy University Hospital were consecutively screened for inclusion from November 2016-February 2017. Data about hospitalisation, surgery, medication, outpatient visits, investigations and transport over the previous 12 months were retrospectively collected. RESULTS: A total of 108 patients (n = 83 Crohn's disease; n = 25 ulcerative colitis) were included. The mean annual cost per patient was €15,775 (standard deviation €7221), with no difference between Crohn's disease and ulcerative colitis (p = 0.2). The main cost driver was medication, which accounted for 84% of the total direct cost. Hospitalisation and surgery represented 11% and 2% of the direct costs. History of switch to another anti-tumour necrosis factor treatment was identified as the only independent predictor of greater direct costs in the multivariate analysis (p = 0.0018). CONCLUSIONS: In a French tertiary referral centre, direct costs of anti-tumour necrosis factor therapy-treated patients were mainly driven by medication, while hospitalisation and surgery represented only a minor part of the costs. There was no difference between Crohn's disease and ulcerative colitis patients.

Dates and versions

hal-02548450 , version 1 (20-04-2020)

Identifiers

Cite

Jean Lawton, Hamza Achit, Lieven Pouillon, Emmanuelle Boschetti, Béatrice Demoré, et al.. Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience. United European Gastroenterology Journal, 2019, 7 (7), pp.908-913. ⟨10.1177/2050640619853448⟩. ⟨hal-02548450⟩
36 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More